all report title image

Pharmacogenomics Market, By Technology (DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, and Others), By Application (Cardiovascular Diseases, Infectious Diseases, Oncology, Neurological Diseases, Pain Management, and Others), By End User (Hospitals & Clinics, Research Institutions and Academic Institutes, Diagnostic Laboratories, and Others) By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Apr 2024
  • Code : CMI1053
  • Pages :156
  • Formats :
      Excel and PDF
  • Industry : Biotechnology
Ingographics Image

The global pharmacogenomics market is estimated to be valued at USD 17.19 Bn in 2024 and is expected to exhibit a CAGR of 11.7% during the forecast period (2024-2031). Pharmacogenomics is the branch of science that analyzes how genes affect a person's response to medications. It works on the principle that each person's genetic make-up can influence how their body metabolizes and responds to drugs. With advancements in genetic screening and testing technologies, pharmacogenomics aims to develop personalized prescription approaches that factor in patients' individual genetic profiles. This enables the selection of effective medicines tailored to patients' specific needs while reducing trial-and-error prescribing practices and adverse drug reactions. The global pharmacogenomics market is expected to grow significantly in the coming years as more healthcare systems recognize the clinical utility of this approach in optimizing pharmacotherapy outcomes.

Market Dynamics:

The global pharmacogenomics market is driven by factors such as rising incidences of adverse drug reactions, growing need for personalized medicine, and increasing uptake of companion diagnostics. High research and development expenditures by pharmaceutical companies to develop targeted therapies using pharmacogenomics approaches are also fueling the market growth. However, lack of clinical validation and standardization of genetic tests remains a challenge limiting widespread clinical adoption. Data privacy and ethical concerns related to genetic screening further hamper market expansion. Opportunities lie in incorporating pharmacogenomic testing and profiling into drug trials and regulatory approval processes. Developing affordable pharmacogenetic diagnostic kits and services especially for underpenetrated emerging markets also presents an avenue for market growth.

Key Features of the Study:

  • This report provides an in-depth analysis of the global pharmacogenomics market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
  • It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global pharmacogenomics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this includes Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Pharmigene, Abbott, Agilent Technologies, Inc., QIAGEN, GE HealthCare, Empire Genomics, Inc., Bio-Rad Laboratories, Inc., Oxford Nanopore Technologies plc., PerkinElmer Inc. , Myriad Genetics, Inc., Illumina, Inc., Macrogen, Inc. , BGI Genomics, Eurofins Scientific, MapMyGenome, and Invitae Corporation.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global pharmacogenomics market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pharmacogenomics market.

Detailed Segmentation-

  • By Technology:
    • DNA Sequencing
    • Microarray
    • Polymerase Chain Reaction
    • Electrophoresis
    • Mass Spectrometry
    • Others
  • By Application:
    • Cardiovascular Diseases
    • Infectious Diseases
    • Oncology
    • Neurological Diseases
    • Pain Management
    • Others
  • By End User:
    • Hospitals & Clinics
    • Research Institutions and Academic Institutes
    • Diagnostic Laboratories
    • Others
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa

Company Profiles:

  • Thermo Fisher Scientific Inc.
  • Hoffmann-La Roche Ltd
  • Pharmigene
  • Abbott
  • Agilent Technologies, Inc.
  • QIAGEN
  • GE HealthCare
  • Empire Genomics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Oxford Nanopore Technologies plc.
  • PerkinElmer Inc.
  • Myriad Genetics, Inc.
  • Illumina, Inc.
  • Macrogen, Inc.
  • BGI Genomics
  • Eurofins Scientific
  • MapMyGenome
  • Invitae Corporation

Detailed Segmentation-

  • By Technology:
    • DNA Sequencing
    • Microarray
    • Polymerase Chain Reaction
    • Electrophoresis
    • Mass Spectrometry
    • Others
  • By Application:
    • Cardiovascular Diseases
    • Infectious Diseases
    • Oncology
    • Neurological Diseases
    • Pain Management
    • Others
  • By End User:
    • Hospitals & Clinics
    • Research Institutions and Academic Institutes
    • Diagnostic Laboratories
    • Others
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.